Metastatic HR+

Metastatic HR+

1. OncUpdates presentation on Ribociclib and oral SERDs in high-risk cancer disease featuring expert oncologists and researchers.

Metastatic HR+

01/14/2026

Ep. 4: Ribociclib and the Evolving Role of Oral SERDs in High-Risk Disease

Laura Huppert, MDKomal Jhaveri, MD, FACPHeather McArthur, MDHope Rugo, MD, FASCORahul Gosain, MD, MBARohit Gosain, MD
OncUpdates panel discussing Abemaciclib vs Ribociclib for clinical decision-making and improving quality of life in cancer patients, featuring expert oncologists Dr. Rohit Gosain, Dr. Rahul Gosain, Dr. Laura Huppert, Dr. Komal Jhaveri, Dr. Hope Rugo, and Dr. Heather McArthur.

Metastatic HR+

01/12/2026

Ep. 3: Abemaciclib vs Ribociclib: Clinical Decision-Making for Quality of Life

Laura Huppert, MDKomal Jhaveri, MD, FACPHeather McArthur, MDHope Rugo, MD, FASCORahul Gosain, MD, MBARohit Gosain, MD
1. OncUpdates panel discussing metastatic HR+ breast cancer and CDK4/6 inhibitor treatment options with leading oncology experts.

Metastatic HR+

01/10/2026

Ep. 2: Metastatic HR-Positive Breast Cancer: Choosing the Right CDK4/6 Inhibitor

Laura Huppert, MDKomal Jhaveri, MD, FACPHeather McArthur, MDHope Rugo, MD, FASCORahul Gosain, MD, MBARohit Gosain, MD
OncUpdates medical experts discussing clinical insights on optimizing Ribociclib, Abemaciclib, and Palbociclib for cancer treatment.

Metastatic HR+

01/06/2026

Ep. 1: Clinical Insights: Optimizing Ribociclib, Abemaciclib, and Palbociclib Use in Metastatic HR-Positive Breast Cancer

Laura Huppert, MDKomal Jhaveri, MD, FACPHeather McArthur, MDHope Rugo, MD, FASCORahul Gosain, MD, MBARohit Gosain, MD
1. Expert panel discusses CDK4/6 inhibitors in metastatic breast cancer at OncUpdates, featuring leading oncologists and researchers.

Metastatic HR+

12/31/2025

CDK4/6 Inhibitor Selection in HR+ Metastatic Breast Cancer (Full Video)

Laura Huppert, MDKomal Jhaveri, MD, FACPHeather McArthur, MDHope Rugo, MD, FASCORahul Gosain, MD, MBARohit Gosain, MD